A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Read more about A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Read more about Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Read more about Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.
Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Read more about Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Read more about Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Read more about XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.
FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Read more about FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo.
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Read more about p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).
Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Read more about Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab.
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Read more about Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.
